新型CDK4/6抑制剂palbociclib  

A novel CDK4/6 inhibitor,palbociclib

作　　者：范丽萍[1,2,3] 焦园园[1,2] 郭子寒 张艳华[1,2] 

机构地区：[1]北京大学肿瘤医院 [2]北京市肿瘤防治研究所药剂科恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142 [3]北京大学医学部药事管理与临床药学系,北京100191

出　　处：《中国新药杂志》2015年第19期2161-2163,2202,共4页Chinese Journal of New Drugs

摘　　要：palbocicib是一种口服的CDK4/6抑制剂,能够选择性抑制CDK4/6,恢复细胞周期控制,阻断肿瘤细胞增殖。2015年2月本品由美国FDA经加速批准途径获准上市,与来曲唑联用适用于绝经后ER阳性、HER2阴性的晚期乳腺癌患者转移性疾病的初始内分泌治疗。该药是一种全新作用机制的抗乳腺癌药,入世后临床使用效果良好,主要不良反应为中性粒细胞减少。本文对其作用机制、药效学、药动学、临床试验、用法与用量、药物相互作用、安全性以及特殊人群用药等方面做一综述。Palbociclib is an oral selective inhibitor of cyclin-dependent kinase（ CDK） 4 and 6,which can restore the control of cell cycle and block the proliferation of tumor cells. In February 2015,palbociclib was approved by the accelerated approval process of the US FDA,and indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor（ ER）-positive,human epidermal growth factor receptor 2（ HER2）-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. The drug is an anti-breast cancer drug of new mechanism and has desirable efficacy. The main adverse reaction is neutropenia. In this article,the mechanism,pharmacokinetics,pharmacodynamics,clinical studies,dosage and administration,drug interactions,safety and use of palbociclib in specific population were reviewed.

关 键 词：新型CDK4/6抑制剂 乳腺癌 palbociclib 

分 类 号：R979.1[医药卫生—药品]